DHEA metabolism in prostate: For better or worse?

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 83-88

  Arnold, Julia T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Androgen receptor; Coculture; DHEA; Epithelial prostate; Estrogen receptor; PSA; Red clover isoflavones; Stromal; Testosterone; TGF 1

Indexed keywords

ESTRADIOL; PRASTERONE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN METABOLISM; CANCER GROWTH; CANCER RISK; CELL COMPARTMENTALIZATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; HORMONE RELEASE; HUMAN; IN VITRO STUDY; MICROENVIRONMENT; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

DEHYDROEPIANDROSTERONE; EPITHELIUM; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; STROMAL CELLS;

EID: 60249098570     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.10.019     Document Type: Review

References (67)

1. Agarwal A.K., and Auchus R.J. Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 146 (2005) 2531-2538
2. Akwa Y., and Baulieu E.E. Dehydroepiandrosterone sulfate and dehydroepiandrosterone: Neuroactive neurosteroids. Curr. Opin. Endocrinol. Diab. 7 (2000) 160-167
3. Alesci S., Manoli I., and Blackman M.R. Dehydrodepiandrosterone (DHEA). In: Coates P., et al. (Ed). Encyclopedia of Dietary Supplements. 1st ed. (2005), Marcel Dekker, Inc., New York, NY 167-176
4. Arnold J.T., and Blackman M.R. Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer?. Endocrinology 146 (2005) 4565-4567
5. Arnold J.T., and Isaacs J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr. Relat. Cancer 90 (2002) 61-73
6. Arnold J.T., Le H., McFann K.K., and Blackman M.R. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E573-E584
7. Arnold J.T., Liu X., Allen J.D., Le H., McFann K.K., and Blackman M.R. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E2-induced proliferation and PSA production in human prostate cancer cells. Prostate 67 (2007) 1152-1162
8. Arnold J.T., Gray N.E., Jacobowitz K., Viswanathan L., Cheung P.W., McFann K.K., Le H.D., and Blackman M.R. Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J. Steroid Biochem. Mol. Biol. 11 (2008) 240-246
9. Belanger A., Candas B., Dupont A., Cusan L., Diamond P., Gomez J.L., and Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J. Clin. Endocrinol. Metab. 79 (1994) 1086-1090
10. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19 (2005) 833-842
11. Carruba G. Estrogens and mechanisms of prostate cancer progression. Ann. N.Y. Acad. Sci. 1089 (2006) 201-217
12. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J. Cell Biochem. 102 (2007) 899-911
13. Cavalieri E.L., and Rogan E.G. A unified mechanism in the initiation of cancer. Ann. N.Y. Acad. Sci. 959 (2002) 341-354
14. Chang W.Y., and Prins G.S. Estrogen receptor-beta: implications for the prostate gland. Prostate 40 (1999) 115-124
15. Chen F., Knecht K., Birzin E., Fisher J., Wilkinson H., Mojena M., Moreno C.T., Schmidt A., Harada S., Freedman L.P., and Reszka A.A. Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology 146 (2005) 4568-4576
16. Ciolino H., MacDonald C., Memon O., Dankwah M., and Yeh G.C. Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo. Int. J. Cancer 105 (2003) 321-325
17. Corey E., Quinn J.E., Emond M.J., Buhler K.R., Brown L.G., and Vessella R.L. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin. Cancer Res. 8 (2002) 1003-1007
18. Cunha G.R., Cooke P.S., and Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch. Histol. Cytol. 67 (2004) 417-434
19. De Marzo A.M., Marchi V.L., Epstein J.I., and Nelson W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155 (1999) 1985-1992
20. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., Nakai Y., Isaacs W.B., and Nelson W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7 (2007) 256-269
21. Deutsch E., Maggiorella L., Eschwege P., Bourhis J., Soria J.C., and Abdulkarim B. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol. 5 (2004) 303-313
22. Donjacour A.A., and Cunha G.R. Stromal regulation of epithelial function. Cancer Treat. Res. 53 (1991) 335-364
23. Dulos J., and Boots A.H. DHEA metabolism in arthritis: a role for the p450 enzyme Cyp7b at the immune-endocrine crossroad. Ann. N.Y. Acad. Sci. 1069 (2006) 401-413
24. Ee Y.S., Lai L.C., Reimann K., and Lim P.K. Effect of transforming growth factor-beta1 on oestrogen metabolism in MCF-7 and MDA-MB-231 breast cancer cell lines. Oncol. Rep. 6 (1999) 843-846
25. Ellem S.J., and Risbridger G.P. Aromatase and prostate cancer. Miner. Endocrinol. 31 (2006) 1-12
26. Ellem S.J., and Risbridger G.P. Treating prostate cancer: a rationale for targeting local oestrogens. Nat. Rev. Cancer 7 (2007) 621-627
27. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin. Oncol. 12 (1985) 28-35
28. Gingras S., and Simard J. Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. Endocrinology 140 (1999) 4573-4584
29. Gray, N.E., Liu, X., Choi, R., Blackman, M.R., Arnold, J.T., in press. Endocrine-immune-paracrine interactions in prostate cells: a model for mechanistic studies of phytomedicines. Cancer Prev. Res.
30. Green J.E., Shibata M.A., Shibata E., Moon R.C., Anver M.R., Kelloff G., and Lubet R. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 61 (2001) 7449-7455
31. Ho C.K., Nanda J., Chapman K.E., and Habib F.K. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J. Endocrinol. 197 (2008) 483-491
32. Howes J., Waring M., Huang L., and Howes L.G. Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense). J. Altern. Complement. Med. 8 (2002) 135-142
33. Hsing A.W., Chu L.W., and Stanczyk F.Z. Androgen and prostate cancer: is the hypothesis dead?. Cancer Epidemiol. Biomark. Prev. 17 (2008) 2525-2530
34. Isaacs J.T. The aging ACI/Seg versus copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res. 44 (1984) 5785-5796
35. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6 (2006) 392-401
36. Klein H., Bressel M., Kastendieck H., and Voigt K.D. Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J. Steroid Biochem. 30 (1988) 119-130
37. Klein H., Molwitz T., and Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia: characterization and quantification of the enzyme in epithelium and stroma. J. Steroid Biochem. 33 (1989) 195-200
38. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78 (1991) C113-C118
39. Labrie F., Dupont A., Simard J., Luu-The V., and Belanger A. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol. 24 Suppl. 2 (1993) 94-105
40. Labrie F., Belanger A., Luu-The V., Labrie C., Simard J., Cusan L., Gomez J.L., and Candas B. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63 (1998) 322-328
41. Le H., Arnold J.T., McFann K.K., and Blackman M.R. Dihydrotestosterone and Testosterone, but not DHEA or estradiol, differentially modulate IGF-I, IGFBP-2 and IGFBP-3 gene and protein expression in primary cultures of human prostatic stromal cells. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E952-E960
42. Lubet R.A., Gordon G.B., Prough R.A., Lei X.D., You M., Wang Y., Grubbs C.J., Steele V.E., Kelloff G.J., Thomas C.F., and Moon R.D. Modulation of methylnitrosourea-induced breast cancer in Sprague-Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res. 58 (1998) 921-926
43. Martin L.J., and Boyd N.F. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res. 10 (2008) 201
44. Martin C., Ross M., Chapman K.E., Andrew R., Bollina P., Seckl J.R., and Habib F.K. CYP7B generates a selective estrogen receptor beta agonist in human prostate. J. Clin. Endocrinol. Metab. 89 (2004) 2928-2935
45. McPherson S.J., Ellem S.J., Simpson E.R., Patchev V., Fritzemeier K.H., and Risbridger G.P. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 148 (2007) 566-574
46. McPherson S.J., Ellem S.J., and Risbridger G.P. Estrogen-regulated development and differentiation of the prostate. Differentiation 76 (2008) 660-670
47. Peehl D.M., and Sellers R.G. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp. Cell Res. 232 (1997) 208-215
48. Perkins S.N., Hursting S.D., Haines D.C., James S.J., Miller B.J., and Phang J.M. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis 18 (1997) 989-994
49. Petricoin III E.F., Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., Velassco A., Trucco C., Wiegand L., Wood K., Simone C.B., Levine P.J., Linehan W.M., Emmert-Buck M.R., Steinberg S.M., Kohn E.C., and Liotta L.A. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94 (2002) 1576-1578
50. Pike M.C., Krailo M.D., Henderson B.E., Casagrande J.T., and Hoel D.G. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303 (1983) 767-770
51. Rainey W.E., Naville D., and Mason J.I. Regulation of 3 beta-hydroxysteroid dehydrogenase in adrenocortical cells: effects of angiotensin-II and transforming growth factor beta. Endocr. Res. 17 (1991) 281-296
52. Rannikko A., Petas A., Rannikko S., and Adlercreutz H. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation. Prostate 66 (2006) 82-87
53. Rao K.V., Johnson W.D., Bosland M.C., Lubet R.A., Steele V.E., Kelloff G.J., and McCormick D.L. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 59 (1999) 3084-3089
54. Regelson W., Loria R., and Kalimi M. Hormonal intervention: "buffer hormones" or "state dependency". The role of dehydroepiandrosterone (DHEA), thyroid hormone, estrogen and hypophysectomy in aging. Ann. N.Y. Acad. Sci. 521 (1988) 260-273
55. Risbridger G.P., Ellem S.J., and McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J. Mol. Endocrinol. 39 (2007) 183-188
56. Rowley D.R. What might a stromal response mean to prostate cancer progression?. Cancer Metast. Rev. 17 (1998) 411-419
57. Schedin P., and Elias A. Multistep tumorigenesis and the mircroenvironment. Breast Cancer Res. 6 (2004) 93-101
58. Schwartz A.G., and Pashko L.L. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J. Cell. Biochem. 22 Suppl. (1995) 210-217
59. Signoretti S., and Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator?. Am. J. Pathol. 159 (2001) 13-16
60. Simard J., and Gingras S. Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Mol. Cell. Endocrinol. 171 (2001) 25-40
61. Smithers D. On some general concepts in oncology with special reference to Hodgkins's disease. Int. J. Radiat. Oncol. Biol. Phys. 9 (1983) 731-738
62. Tuxhorn J.A., Ayala G.E., and Rowley D.R. Reactive stroma in prostate cancer progression. J. Urol. 166 (2001) 2472-2483
63. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., and Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8 (2002) 2912-2923
64. Voigt K.D., and Bartsch W. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J. Steroid Biochem. 25 (1986) 749-757
65. Weihua Z., Makela S., Andersson L.C., Salmi S., Saji S., Webster J.I., Jensen E.V., Nilsson S., Warner M., and Gustafsson J.A. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6330-6335
66. Weihua Z., Warner M., and Gustafsson J.A. Estrogen receptor beta in the prostate. Mol. Cell. Endocrinol. 193 (2002) 1-5
67. Widstrom R.L., and Dillon J.S. Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate?. Semin. Reprod. Med. 22 (2004) 289-298